New hope for HER2+ breast cancer patients who stopped responding to standard therapy
NCT ID NCT07366840
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a drug called RC48, combined with chemotherapy, works better than standard treatments for women with advanced HER2-positive breast cancer whose disease has progressed after prior therapy. About 268 participants will be randomly assigned to receive either RC48 plus chemo or standard trastuzumab/inetetamab plus chemo. The main goal is to see how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Disitamab vedotin (RC48) combined with gemcitabine or capecitabine, with or without trastuzumab or inetetamab
- What this could lead to
- If successful, this could offer a new treatment option for HER2-positive advanced breast cancer patients whose disease has worsened after prior antibody-drug conjugate therapy.
- What could go wrong
- This is an early-phase 2/3 trial with only 268 participants, so results may not apply to all patients. The combination therapy may cause side effects like nerve damage, low blood counts, or heart issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer